Bright times for Sunshine Heart as it CE marks C-Pulse heart assist device; US approval in 2016?
This article was originally published in Clinica
Executive Summary
Sunshine Heart has CE marked its C-Pulse heart assist system, a potentially game-changing device for treating heart failure, for sale in Europe. The Eden Prairie, Minnesota company's share price on the Nasdaq Capital Market reached a high of $13.69 during trading on 25 July, the day the news was announced, but has since fallen to pre-approval levels of around $10.00.